

- to the Committee's scope
- b. Interest and Motivation
 - (i) Explanation of why the nominee wants to serve on the Committee
 - (ii) How their participation would benefit the Committee's objective to Make America Healthy Again
- c. Representative Member Declaration (*if applicable, required to include with submission for nomination to be considered*)
 - (i) Clear identification of the organization, constituency, or stakeholder group
 - (ii) Explanation of why the nominee has authority to speak on behalf of the represented group
- d. Availability and Commitment Statement
 - (i) Confirmation of ability to attend meetings and fulfill time commitments
 - (ii) Acknowledgment of expected service duration
 - (iii) Any potential scheduling constraints or conflicts
- e. Nominee Eligibility Confirmation
 - (i) Statement affirming nominee meets all Committee eligibility criteria, specifically addressing that the nominee:
 - (1) Is a U.S. citizen; and
 - (2) Is not required to register as a foreign agent under the Foreign Agents Registration Act of 1938, as amended.

3. Supporting Documentation

- a. Biography
 - (i) Professional and academic credentials
- b. Resume or Curriculum Vitae
 - (i) Educational experience, as well as relevant professional experience
 - (ii) Publications or work samples that demonstrate expertise
 - (1) Do not include brochures or any other promotional information.
 - (iii) Previous experience on a Federal Advisory Committee (*if applicable*)
- c. Two Letters of Reference
 - (i) Support the nominee's qualifications for participation on the Committee (*For nominations other than self-nominations, a third-party nomination letter that includes information supporting the nominee's qualifications may be counted as one of the letters of reference*)

Materials submitted should total 10 pages or less. Should more information be needed, Department staff will contact the applicant/nominee, obtain information from the applicant's/nominee's past affiliations, or obtain information from publicly available sources.

HHS will prioritize appointing Committee members who possess practical and tactical experience or expertise necessary to address the Make America Healthy Again objectives and advocate for key stakeholder interests. Representative Members will be appointed based on their ability to provide the point of view of an organization, group, or industry with an interest in the matters before the Committee. Representative Member selection criteria includes but is not limited to: years of experience effectively representing stakeholder groups, industries, or constituencies; demonstrated advocacy success; strong communication and analytical skills; established credibility within their representative sector; and ability to balance constituent interests with committee objectives. Nominees being considered for an SGE position will be subject to a conflict-of-interest review in accordance with government ethics law and regulation prior to their appointment and will be chosen for their ability and to provide independent expert advice to the Agency. SGEs will be appointed based on the individual's ability to provide independent advice to the Agency. SGE selection criteria includes but is not limited to: years of experience as a technical advisor in the candidate's specialized field; track record of publishing research findings while working in academia; and ability to balance independent expertise with collaborative committee participation.

To the extent permitted by FACA and other laws, the Committee membership shall also be consistent with achieving the greatest impact, scope, and credibility among diverse stakeholders. In making such appointments, HHS shall ensure a fair balance among viewpoints from all relevant stakeholders, broad geographic representation—including both urban and rural perspectives—and diversity across demographic characteristics, including race, ethnicity, sex, disability status, and socioeconomic background. HHS will also seek representation from stakeholders across relevant sectors, including patients, providers, payers, academia, community-based organizations, and regional, State and local government. HHS reserves the discretion to appoint Committee members from outside the pool of respondents to this notice if such appointments are necessary to fulfill specific expertise requirements in a

manner to ensure an appropriate balance of membership.

Robert F. Kennedy, Jr.,
Secretary, Department of Health and Human Services.

[FR Doc. 2025–16136 Filed 8–21–25; 11:15 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Amended Notice of Partially Closed Meeting

Notice is hereby given of a change in the meeting of the National Advisory Council on Drug Abuse, September 9, 2025, 10:30 a.m. to 5:00 p.m., National Institutes of Health, Neuroscience Center, Conference Room 1145/1155, 6001 Executive Boulevard Rockville, MD 20852 which was published in the **Federal Register** on August 15, 2025, FR Doc 2025–15505, 90 FR 39410.

This meeting notice is being amended to change the open session's virtual access location. The open session of the meeting can be accessed from the NIH Videocast at the following link: <https://videocast.nih.gov/>. The meeting is partially closed to the public.

Dated: August 19, 2025.

David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–16058 Filed 8–21–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Integrative, Functional and Cognitive Neuroscience Integrated Review Group; Sensory-Motor Neuroscience Study Section.

Date: September 25–26, 2025.

Time: 10:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Alena Valeryevna Savonenko, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1009J, Bethesda, MD 20892, (301) 594-3444, savonenkoa2@csr.nih.gov.

Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group Pathophysiology of Eye Disease—1 Study Section

Date: September 29–30, 2025

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications

Address: National Institutes of Health Rockledge II 6701 Rockledge Drive Bethesda, MD 20892

Meeting Format: Virtual Meeting

Contact Person: Afia Sultana, Ph.D. Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4189, Bethesda, MD 20892, (301) 827-7083, sultanaa@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: August 19, 2025.

Sterlyn H. Gibson,

Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–16059 Filed 8–21–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center For Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Genes, Genomes, and Genetics Integrated Review Group;

Genomics, Computational Biology and Technology Study Section.

Date: October 2–3, 2025.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Methode Bacanamwo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2200, Bethesda, MD 20892, 301-827-7088, methode.bacanamwo@nih.gov.

Name of Committee: Genes, Genomes, and Genetics Integrated Review Group; Maximizing Investigators' Research Award A Study Section.

Date: October 6–7, 2025.

Time: 9:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Mollie Kim Manier, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-0510, mollie.manier@nih.gov.

Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group; Innovations in Nanosystems and Nanotechnology Study Section.

Date: October 8–9, 2025.

Time: 9:30 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Yingli Fu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-0840, yingli.fu@nih.gov.

Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group; Drug and Biologic Therapeutic Delivery Study Section.

Date: October 9–10, 2025.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Janice Duy, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-3139, janice.duy@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: August 20, 2025.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–16169 Filed 8–21–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG–2025–0198]

Information Collection Request to Office of Management and Budget; OMB Control Number: 1625–0039

AGENCY: Coast Guard, DHS.

ACTION: Sixty-day notice requesting comments.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the U.S. Coast Guard intends to submit an Information Collection Request (ICR) to the Office of Management and Budget (OMB), Office of Information and Regulatory Affairs (OIRA), requesting an extension of its approval for the following collection of information: 1625–0039, Declaration of Inspection Before Transfer of Liquid Cargo in Bulk; without change. Our ICR describes the information we seek to collect from the public. Before submitting this ICR to OIRA, the Coast Guard is inviting comments as described below.

DATES: Comments must reach the Coast Guard on or before October 21, 2025.

ADDRESSES: You may submit comments identified by Coast Guard docket number [USCG–2025–0198] to the Coast Guard using the Federal eRulemaking Portal at <https://www.regulations.gov>. See the “Public participation and request for comments” portion of the **SUPPLEMENTARY INFORMATION** section for further instructions on submitting comments.

A copy of the ICR is available through the docket on the internet at <https://www.regulations.gov>. Additionally, copies are available from: Commandant (CG–C5I–P), Attn: PaperWork Reduction Act Manager, U.S. Coast Guard, 2703 Martin Luther King Jr. Ave. SE, Stop 7710, Washington, DC 20593–7710.

FOR FURTHER INFORMATION CONTACT: A.L. Craig, Office of Privacy Management, telephone (571) 607–4058, or email hqs-dg-m-cg-61-pii@uscg.mil for questions on these documents.

SUPPLEMENTARY INFORMATION: